Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

7.22
-0.3200-4.24%
Post-market: 7.230.0100+0.14%19:15 EDT
Volume:1.20M
Turnover:8.70M
Market Cap:596.17M
PE:-2.10
High:7.53
Open:7.48
Low:7.15
Close:7.54
52wk High:13.24
52wk Low:2.68
Shares:82.57M
Float Shares:49.97M
Volume Ratio:0.67
T/O Rate:2.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4360
EPS(LYR):-3.0696
ROE:-90.88%
ROA:-43.24%
PB:2.83
PE(LYR):-2.35

Loading ...

Replimune Group Inc : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $13 From $8

THOMSON REUTERS
·
Oct 21, 2025

Replimune upgraded to Overweight from Neutral at Piper Sandler

TIPRANKS
·
Oct 21, 2025

Replimune upgraded to Neutral from Underweight at JPMorgan

TIPRANKS
·
Oct 21, 2025

Top Midday Gainers

MT Newswires Live
·
Oct 21, 2025

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today

Benzinga_recent_news
·
Oct 21, 2025

Leerink upgrades Replimune on renewed confidence in RP1

TIPRANKS
·
Oct 20, 2025

Replimune upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
Oct 20, 2025

Stock Track | Replimune Soars Over 100% as FDA Accepts Resubmission for Melanoma Treatment

Stock Track
·
Oct 20, 2025

Shares of Replimune More Than Double After US FDA Accepts Resubmission for Potential Approval of Skin Cancer Drug

THOMSON REUTERS
·
Oct 20, 2025

Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results

Benzinga
·
Oct 20, 2025

Unusually active option classes on open October 20th

TIPRANKS
·
Oct 20, 2025

Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts Price Target to $18 From $4

MT Newswires Live
·
Oct 20, 2025

Replimune Group Raised to Outperform From Neutral by Wedbush

Dow Jones
·
Oct 20, 2025

Why Is Replimune Stock (REPL) Up 105% Today?

TIPRANKS
·
Oct 20, 2025

Replimune upgraded to Outperform from Neutral at Wedbush

TIPRANKS
·
Oct 20, 2025

Replimune Shares Extend Premarket Gains, Last up 92%

THOMSON REUTERS
·
Oct 20, 2025

Replimune Shares Soar After FDA Accepts Melanoma Treatment Resubmission

Dow Jones
·
Oct 20, 2025

BUZZ-Replimune jumps after FDA accepts resubmission for skin cancer drug

Reuters
·
Oct 20, 2025

Shares of Replimune Group Rise 75.8% Premarket After US FDA Accepts Resubmission for Potential Approval of Skin Cancer Drug

THOMSON REUTERS
·
Oct 20, 2025

Replimune Group Inc: Pdufa Date Set by FDA for Rp1 Is April 10, 2026

THOMSON REUTERS
·
Oct 20, 2025